How the Eli Lilly Foundayo weight loss pill reaches Medicare patients for a $50 copay

Millions of older Americans who have watched blockbuster weight-loss drugs stay just out of financial reach are about to get a foot in the door. Beginning July 1, 2026, eligible Medicare beneficiaries can obtain Eli Lilly's newly approved oral obesity pill, Foundayo, along with several rival GLP-1 medications, for a flat $50 copay each month under a federal demonstration program that runs through the end of 2027.

The move stitches together two of the most closely watched stories in American medicine this year: the arrival of a convenient once-daily weight-loss pill, and the long-contested question of whether Medicare should pay for obesity treatment at all. For a program that has historically been barred from covering drugs used solely for weight loss, the new "Medicare GLP-1 Bridge" demonstration marks a significant, if temporary, shift in federal policy.

A once-daily tablet clears the FDA in record time

The Food and Drug Administration approved Eli Lilly's Foundayo, known generically as orforglipron, on April 1, 2026, following a fast-tracked review that took just 50 days. The green light made Foundayo the second oral GLP-1 weight-loss pill to reach the U.S. market, arriving several months after Novo Nordisk's oral version of Wegovy, which was approved in December 2025.

What separates Foundayo from earlier entrants is chemistry and convenience. It is a small-molecule, non-peptide GLP-1 receptor agonist, meaning it can be swallowed like an ordinary pill and taken at any time of day without the food and water restrictions that hobble competing products. Novo Nordisk's oral Wegovy, by contrast, must be taken on an empty stomach, a requirement that can complicate daily routines and adherence.

That ease of use is central to Lilly's pitch. Injectable GLP-1 drugs have driven a cultural and commercial phenomenon, but needles, refrigeration, and supply constraints have limited who sticks with them. A tablet that fits into a morning cup of coffee, with no timing rules attached, is precisely the kind of product that could broaden the market well beyond early adopters.

What the ATTAIN-1 trial actually showed

The clinical case for Foundayo rests largely on the Phase 3 ATTAIN-1 trial, which enrolled more than 3,000 adults living with obesity. Patients taking the highest 36 mg dose lost an average of 11.2% to 12.4% of their body weight, roughly 25 to 27.3 pounds, over 72 weeks. Participants on placebo lost about 2.1%, or somewhere between 2 and 5 pounds.

To improve tolerability, the drug is titrated slowly. Treatment starts at 0.8 mg and steps up roughly every 30 days, moving through 2.5 mg, 5.5 mg, 9 mg, and 14.5 mg, on the way to 17.2 mg or higher. That gradual ramp is designed to give the digestive system time to adjust, a familiar strategy across the GLP-1 class.

The results are meaningful, but they should be read in context. Double-digit average weight loss from a pill represents a genuine clinical advance for many patients. Yet the same data also make clear that Foundayo is not the most powerful option on pharmacy shelves, a point that matters a great deal once patients start comparing their choices under the new Medicare benefit.

Eli Lilly Foundayo weight loss pill

Head-to-head trial comparisons put Foundayo in the middle of the pack. Injectable competitors post larger average reductions: Zepbound, also made by Lilly and based on tirzepatide, produces weight loss of around 21%, while injectable Wegovy lands near 15%. Foundayo's roughly 11% to 12% at its top dose is respectable, but it is noticeably less than what a needle can deliver.

For clinicians, that gap frames a familiar trade-off between potency and convenience. A patient who prizes simplicity, or who is needle-averse, may happily accept a somewhat smaller result in exchange for a pill. A patient with a higher body mass index or a pressing cardiometabolic condition might prioritize maximum weight loss and opt for an injection despite the added hassle.

The Eli Lilly Foundayo weight loss pill therefore occupies a distinct niche. It is not positioned as the strongest drug in the obesity arsenal, but rather as the most accessible one, a product built to convert hesitant patients and reach people the injectables never touched. That positioning becomes especially important now that the federal government is helping foot the bill.

Inside the Medicare GLP-1 Bridge demonstration

The centerpiece of the July 1 rollout is the Centers for Medicare and Medicaid Services demonstration formally called the Medicare GLP-1 Bridge. Under the program, eligible Medicare Part D beneficiaries can obtain Foundayo, Wegovy in either its injection or tablet form, or Zepbound for a flat $50 copay per 30-day supply. The demonstration is scheduled to run through December 31, 2027.

The design is deliberately temporary, a bridge rather than a permanent benefit. It gives federal officials a defined window to gather real-world data on cost, uptake, and health outcomes before deciding whether broader, lasting coverage is justified. For beneficiaries, it offers a rare chance to try medications that have often carried monthly price tags in the hundreds of dollars.

There is a notable catch buried in the fine print. The $50 copay does not count toward the Part D deductible or the annual out-of-pocket cap. In practical terms, the money a beneficiary spends on these drugs sits outside the usual spending protections, so it does not accelerate the point at which other prescription costs become cheaper.

Eligibility rules tied to BMI and health risks

Eligibility for the Bridge is tied to body mass index and accompanying health risks rather than weight alone. Beneficiaries qualify with a BMI of 35 or higher outright. Those with a BMI between 30 and 34.9 can qualify if they also have a qualifying condition such as heart failure, hypertension, chronic kidney disease, prediabetes, a prior heart attack or stroke, or peripheral artery disease.

The door opens even further for patients at lower weights who carry specific risks. A beneficiary with a BMI of 27 or above may qualify if they have prediabetes or documented cardiovascular risk. The framework reflects a growing medical consensus that obesity is best treated as a driver of other serious diseases, not simply as a cosmetic concern.

That structure also signals how federal officials are trying to contain costs. By anchoring access to established cardiometabolic conditions, the program aims to direct these expensive medications toward the patients most likely to see downstream health benefits, rather than opening an unlimited entitlement.

The price ladder outside of Medicare

For patients who do not fall under the demonstration, Foundayo's cost varies widely depending on insurance. Using Eli Lilly's savings card, insured patients can pay as little as $25 per month. Cash-pay patients, however, face a steeper range of $149 to $349 per month depending on the dose they are prescribed.

That spread illustrates the fractured economics of the GLP-1 boom. The list price and the actual out-of-pocket price can diverge dramatically based on coverage, discount programs, and negotiated rebates. For an uninsured worker, the same tablet that costs a Medicare beneficiary $50 could cost several times that amount.

The pricing picture helps explain why the Medicare demonstration is so consequential. It does not merely add a new payer; it establishes a predictable, capped price for a population that has often been priced out entirely, and it does so for a drug class where affordability has been the central barrier to adoption.

Side effects and the tolerability question

Like other drugs in its class, Foundayo comes with a familiar roster of gastrointestinal side effects. The most common include nausea, constipation, diarrhea, vomiting, indigestion, and stomach pain, along with headache, fatigue, and hair loss. These effects are the reason the drug is titrated so slowly over successive months.

Tolerability shows up in the discontinuation numbers. Roughly 5% to 10% of trial participants stopped taking Foundayo because of GI side effects, compared with about 3% on placebo. That gap is meaningful, and it suggests that a subset of patients will find the drug difficult to stay on even at a manageable price.

For prescribers and patients weighing options under the Bridge program, side effects add another dimension to an already layered decision. The calculus involves not only how much weight a drug can shed and what it costs, but also how comfortably a person can live with it day to day over the many months required to see results.

Lilly's market grip and the money at stake

Commercially, Foundayo has arrived with force. By around June 2026, Eli Lilly said the drug had already been used to treat more than 20,000 patients and had helped propel the company to roughly 60% of the U.S. GLP-1 market. Wall Street analysts have pegged 2026 sales estimates for Foundayo alone at somewhere between $1.5 billion and $2.8 billion.

Those figures underscore the stakes of the Medicare experiment. A capped copay for a large, previously excluded population could meaningfully expand demand for the Eli Lilly Foundayo weight loss pill and its rivals, reshaping a market that is already one of the most lucrative in modern pharmaceuticals. It also concentrates federal spending on a handful of branded products at a moment of intense scrutiny over drug costs.

The next 18 months will function as a live test of competing propositions: that treating obesity aggressively can prevent costlier disease later, and that a convenient pill can bring durable results at scale. Should the Bridge demonstration show both clinical benefit and manageable cost, it could become the template for permanent Medicare coverage. Should it not, the window closes at the end of 2027, and access narrows again just as quickly as it opened.